Treat-to-Target Improves Fertility in Women with RA https://t.co/q9IMI5UHGO https://t.co/uhqaRXeBRX

JAMA FULL READ review and overview of Axial Spondyloarthritis by Drs. Deodhar & Bittar - Dx often delayed 6-8 yrs - Sensitivity/Specificity of: HLA-B27 (50%/90%), CRP (35%/91%), Xray sacroiliitis (66%/68%) or MRI (78%/88%). Great tables, figs, Xrays &Reference!… https://t.co/MWpznXqPzq https://t.co/46BkH4x9eE

Fibroblastic Rheumatism - JAMA Case: 50yoM w/ 3 yr hx of periarticular nodules, symmetric polyarthralgia at B/L PIPs. These were painful with manipulation or minor trauma. Labs negative. https://t.co/FeLH1GIHr9 https://t.co/Pj1FRHj25u

Biologic Monotherapy vs Combination with cDMARDs in PsA https://t.co/MfqyD6hyOK https://t.co/fRJjOaJ9aT https://t.co/z8gutP79Ub

ICYMI: Shifting Trends in Initial RA Treatment Approaches A recent study by Sparks et al (Abstract #0509) reveals evolving trends in disease-modifying antirheumatic drug (DMARD) usage for RA over two decades in the US. https://t.co/XlMXkuBBVN https://t.co/AHi3DG0aFV https://t.co/vNLF4Ft1GR

DEA and the Department of Health and Human Services (HHS) has extended current telemedicine (TM) flexibilities through end 2025. MDs may Rx meds via TM (including narcotics) without in-office visits. https://t.co/C8lyB5feXg https://t.co/eSjYCnu02Y

#ACR24: Rheumatology Roundup https://t.co/0DMcpsAZce https://t.co/JvMnfAt3EP

Diagnostic Delays in PsA Despite the remarkable expansion of the therapeutic armamentarium for psoriatic arthritis (PsA), the MONITOR-PsA study (abstract 1456) highlights a persistent and critical issue: delays in diagnosis. https://t.co/83TeIpfutP https://t.co/85qo7F9IPa

Off-Label Use of JAK Inhibitors in Orphan Diseases and Other Conditions? The issues surrounding publication bias are real. https://t.co/gIFNjAsoM6 https://t.co/UstQGvJX7H

UK study compared 16,634 female RA pts vs 65,448 controls and found all RA women at incr risk for VTE (thrombosis)[aHR=1.52) irrespective of estrogen contraceptives/HRT. Contraceptives did not increase VTE risk (aHR 2.32; 0.92, 5.85, p=0.08) #ACR24 https://t.co/AzBXI0W5dv https://t.co/Q4TaKq2ReC

Osteoarthritis (OA) affects 53.2 million in the USA & is projected to rise significantly by 2040. Societal costs are $132 billion ($11,00 per/pt). OA is the 3rd most rapidly rising disability, behind diabetes and dementia. https://t.co/n3Rwjjsio3 https://t.co/FPDWd6gEpi